AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE Drug Patent Profile
✉ Email this page to a colleague
When do Azelastine Hydrochloride And Fluticasone Propionate patents expire, and when can generic versions of Azelastine Hydrochloride And Fluticasone Propionate launch?
Azelastine Hydrochloride And Fluticasone Propionate is a drug marketed by Apotex, Padagis Israel, and Teva Pharms Usa Inc. and is included in three NDAs.
The generic ingredient in AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azelastine Hydrochloride And Fluticasone Propionate
A generic version of AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE was approved as azelastine hydrochloride; fluticasone propionate by APOTEX on April 28th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
- What are the global sales for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
- What is Average Wholesale Price for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
Summary for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
